Navirel (Vinorelbine)

Vinorelbine, the active ingredient in Navirel, is a Vinca alkaloid presented as a injection for intravenous use. It treats non‑small cell lung cancer and metastatic breast cancer in adult patients.\n\nGNH India supplies Navirel as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

Vinorelbine is used in oncology to target rapidly dividing tumor cells.\n\nNon‑small cell lung cancer: improves disease control and may extend survival in eligible patients.\nMetastatic breast cancer: employed as a second‑line therapy to reduce tumor burden.

Vinorelbine may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Neutropenia: reduced white blood cell count increasing infection risk.\n- Nausea and vomiting: gastrointestinal upset commonly reported.\n- Fatigue: persistent tiredness during treatment.\n- Alopecia: hair loss affecting scalp and body hair.\n\nSerious or Rare Side Effects:\n- Severe neutropenia with febrile infection.\n- Pulmonary toxicity, including interstitial pneumonitis or fibrosis.\n- Peripheral neuropathy causing numbness or tingling.\n- Anaphylactic reaction: sudden severe allergic response.

Prior to and during Navirel therapy, several safety measures are recommended.\n\nHematologic monitoring: perform regular CBC to detect neutropenia.\nHepatic function: assess liver enzymes before and during therapy.\nCardiac assessment: evaluate baseline ECG and monitor for arrhythmias.\nPregnancy risk: contraindicated in pregnancy; ensure effective contraception.\nDrug handling: use aseptic technique; administer by qualified personnel.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vinorelbine can interact with other medicines, requiring careful management.\n\nMajor Interactions (Avoid):\n- CYP3A4 inhibitors: may increase vinorelbine exposure.\n- Strong CYP3A4 inducers: may reduce efficacy.\n- Concurrent myelosuppressive agents: heightened risk of severe bone marrow suppression.\n\nModerate Interactions (Monitor Closely):\n- Antiemetics such as ondansetron: may affect metabolism.\n- Radiotherapy: overlapping toxicities, especially hematologic.\n- Warfarin: potential for altered coagulation parameters.